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Objectives. We sought to determine predictors of restenosis
after coronary stenting (CS) in a consecutive series of patients.
Background. Although stenting in highly selected patient
groups reduces restenosis, the results of stenting in a heteroge-
neous patient group and the effects of clinical and procedural
factors on stent restenosis are currently unclear.
Methods. We analyzed the 6-month angiographic outcome of
500 lesions in 463 consecutive patients undergoing successful CS.
Clinical, qualitative and quantitative angiographic variables were
correlated with restenosis assessed as both a binary and a
continuous variable.
Results. Restenosis, defined as the presence of >50% diameter
stenosis in the dilated segment, was present in 105 (26%) of the
405 lesions with angiographic follow-up. The mean late lumen loss
during the follow-up period was 0.79 6 0.64 mm. Implantation of
multiple stents (p < 0.0001) and a high acute gain (p < 0.0002)
were independently associated with a higher late lumen loss. In
contrast, the use of high inflation pressure (p < 0.02) and
Palmaz-Schatz stents (p < 0.005) was independently associated
with a lower late lumen loss. When restenosis was defined as a
qualitative variable, implantation of multiple stents (p < 0.001),
stenosis length (p < 0.01), small reference diameter (p < 0.02)
and stent type other than Palmaz-Schatz (p < 0.01) were inde-
pendent predictors of restenosis. None of the clinical variables
tested was associated with restenosis.
Conclusions. Coronary stenting in an unselected patient group
is associated with an acceptable restenosis rate. Although some
risk factors were identified, the risk of restenosis was not related
to most of the variables tested. This suggests that the superiority
of CS over balloon angioplasty, in terms of restenosis, might also
apply to subgroups of patients that were not included in the recent
randomized studies.
(J Am Coll Cardiol 1998;31:1291–8)
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Balloon angioplasty (BA) has become an established treatment
for patients with coronary artery disease (CAD) but remains
plagued by the problem of restenosis (1,2). This has provided
the impetus for the development of newer alternative forms of
coronary revascularization such as coronary stenting (CS).
Follow-up studies after CS have demonstrated relatively low
rates of angiographic and clinical restenosis (3–6). Further-
more, two recent randomized studies have shown that CS is
associated with a significant reduction in the restenosis rate
when compared with BA (7,8); however, these two studies
were performed in highly selected study groups. Subsequent
insights from intracoronary ultrasound studies in humans have
demonstrated different mechanisms of restenosis after BA or
after CS: although chronic remodeling (vessel constriction) is
the major mechanism of restenosis after BA (9), neointimal
thickening is the major mechanism of restenosis after CS, as
the stent prevents the remodeling process (10).
Recent improvements in the technique of stent implanta-
tion and in antithrombotic regimens have allowed CS to be
performed in a high proportion of patients undergoing repeat
percutaneous transluminal coronary angioplasty (PTCA)
(11,12). CS has been reported in rescue situations (13), in
smaller vessels (,3 mm) (14), in diabetic patients (15), in
infarct-related lesions (16,17) and for the treatment of chronic
coronary occlusions (18). Most of these situations have been
associated with high rates of restenosis after BA (19–24);
however, data on their impact on restenosis after CS are still
sparse (4,5,25,26).
The present study was thus designed to analyze the 6-month
angiographic outcome of 500 lesions in 463 consecutive pa-
tients undergoing successful CS. Using quantitative angio-
graphic techniques, we determined both the rate and the
predictors of in-stent restenosis.
Methods
Study group. Between October 1993 and March 1996, 463
consecutive patients underwent successful CS at the Cardiol-
ogy Hospital, Lille. Using standard, previously described tech-
niques (11), CS was performed in 500 lesions in these 463
patients. All patients received antiplatelet therapy. Aspirin
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(100 to 300 mg/day) was started at least 24 h before CS and
continued indefinitely. Ticlopidine (500 mg/day) was started
immediately after CS and continued for 6 weeks. CS was
performed as a bail-out procedure after failed BA, if there was
a suboptimal result after BA or electively. If a single stent did
not entirely cover the lesion, two or three overlapping stents
were implanted. The most frequently used stents were the
14-mm, nonarticulated, Palmaz-Schatz stent (PS 154A) and
the 16-mm Wiktor stent. Other stents were used in only 7% of
lesions. The procedure was considered successful when the
residual lumen narrowing immediately after stent implanta-
tion, estimated visually, was ,30% and when no major com-
plication (electrocardiographic or enzymatic evidence of myo-
cardial infarction, need for coronary artery bypass surgery
during the hospital period or in-hospital death) occurred. At
the time of stenting, all the patients were asked to return for a
6-month follow-up angiogram, regardless of symptomatic sta-
tus; angiography was performed earlier if clinically indicated.
Angiographic follow-up was performed at a mean of 5.8 6 1.8
months after CS in 374 patients (405 lesions [81%]).
Angiographic analyses. Qualitative analyses were per-
formed independently by two experienced interventional car-
diologists. Disagreements were resolved by a further joint
reading. Lesions were classified in accordance with the Amer-
ican Heart Association/American College of Cardiology
(AHA/ACC) classification, as modified by Ellis et al. (27).
Anterograde blood flow was graded using the Thrombolysis in
Myocardial Infarction (TIMI) trial classification (28).
Quantitative computer-assisted angiographic measure-
ments were performed on end-diastolic frames with use of the
Computer-Assisted Evaluation of Stenosis And Restenosis
(CAESAR) system. A detailed description of this system has
been reported previously (29). We routinely perform angiog-
raphy in at least two projections after intracoronary injection
of isosorbide dinitrate (2 mg). These projections are recorded
in our data base, and follow-up angiography is performed, after
injection of isosorbide dinitrate, in the same projections. The
following definitions were used: early gain associated with the
procedure was defined as the difference between the minimal
lumen diameter (MLD) immediately after the procedure and
the MLD before the procedure; late loss during the follow-up
period was defined as the difference between the MLD imme-
diately after the procedure and the MLD at follow-up; net gain
was defined as the difference between the early gain and the
late loss; and restenosis was defined as .50% diameter
stenosis at follow-up.
Statistical analysis. Data are presented as the mean
value 6 SD. For the univariate analysis, continuous variables
were divided into tertiles. Comparisons between groups for
continuous data were made using the Student t test or analysis
of variance followed by the Scheffe´ F test. Differences between
proportions were assessed by chi-square analysis. A value of
p , 0.05 was considered to indicate statistical significance.
Multivariate analysis was performed with SAS software (ver-
sion 6.10; SAS Institute Inc.). To study the relation between a
binary outcome variable and multiple categoric and continuous
determinants, multiple logistic regression analysis was per-
formed. To study the relation between continuous outcome
variables and multiple categoric and continuous determinants,
multiple linear regression was done.
Results
Baseline characteristics. Tables 1 and 2 list the baseline
characteristics of the study group. Most of the patients were
men (mean [6SD] age 59 6 11 years). Nineteen percent of the
patients were diabetics; 36% had CS for unstable angina. The
dilated lesion was located in the left anterior descending
coronary (LAD) in 50% of lesions. Twenty percent of the
lesions were restenotic lesions after BA and 28% were the site
of a recent (,1 month) myocardial infarction. A large variety
of the lesions, in terms of morphologic characteristics, are
shown in Table 2.
CS was performed as a bail-out procedure after failed BA in
14% of patients, because of a suboptimal result after BA in
65% and electively in 21%. Palmaz-Schatz stents were used in
most patients (61%). In 85% of patients, a single stent was
used. High pressure inflation (.12 atm) was used to deploy the
stent in most patients (mean inflation pressure 15 6 3 atm).
Clinical follow-up. Table 3 shows the major cardiac events
during the 6-month follow-up period in the 463 patients who
had successful stent implantation. Seven patients died, four
had a myocardial infarction, 71 underwent a repeat revascu-
larization procedure (bypass surgery in 2 and PTCA in 69).
Abbreviations and Acronyms
ACC 5 American College of Cardiology
AHA 5 American Heart Association
BA 5 balloon angioplasty
CAD 5 coronary artery disease
CS 5 coronary stenting
LAD 5 left anterior descending coronary artery
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction trial
Table 1. Baseline Characteristics: Patient-Related Variables
(n 5 374)
Age (years) 59 6 11
Males 322 (86%)
Diabetes mellitus 72 (19%)
Smoker 264 (71%)
Hypertension 142 (38%)
Hypercholesterolemia 222 (59%)
Family history of
CAD
185 (49%)
Unstable angina 134 (36%)
Data presented are mean value 6 SD or number (%) of patients. CAD 5
coronary artery disease.
1292 BAUTERS ET AL. JACC Vol. 31, No. 6
IN-STENT RESTENOSIS May 1996:1291–8
Early angiographic results and 6-month angiographic
follow-up. The lumen dimensions at baseline, immediately
after the procedure and at follow-up are shown in Table 4 and
Figure 1. CS was associated with an immediate increase in
mean MLD, from 0.78 6 0.45 to 2.57 6 0.43 mm. Mean
percent diameter stenosis decreased from 73 6 15% to 10 6
10%. At follow-up angiography, the mean MLD had decreased
to 1.78 6 0.70 mm, and mean percent stenosis had increased to
37 6 22%. Restenosis, defined as the presence of .50%
diameter stenosis in the dilated segment at follow-up, was
present at 105 (26%) of the 405 lesions with angiographic
follow-up. Of these 105 lesions, 6 (1.5% of the lesions with
follow-up angiography) were totally occluded at follow-up.
Predictors of in-stent restenosis. The univariate predictors
of in-stent restenosis are shown in Tables 5 to 7. We analyzed
both the predictors of lumen narrowing, assessed as a contin-
uous variable (late lumen loss), and the predictors of qualita-
Figure 1. Cumulative distribution curves of MLD at baseline (Pre),
immediately after stent implantation (Post) and at 6-month follow-up
(F-up).
Table 2. Baseline Characteristics: Lesion (n 5 405) and
Procedure-Related Variables
Dilated site
LAD 203 (50%)
LCx 49 (12%)
RCA 128 (32%)
Saphenous vein graft 25 (6%)
Previous PTCA at same site 80 (20%)
Infarct-related lesion 112 (28%)
ACC/AHA classification*
A 38 (9%)
B1 105 (26%)
B2 204 (50%)
C 58 (14%)
TIMI flow grade
0–1 54 (13%)
2 28 (7%)
3 323 (80%)
Calcification 125 (31%)
Eccentric stenosis 183 (45%)
Lesion length (mm) 8.8 6 5.8
Bifurcation lesion 87 (22%)
Bend location 65 (16%)
Thrombus 73 (18%)
Stent indication
Rescue 55 (14%)
Suboptimal result 264 (65%)
Elective 86 (21%)
Type of stent
Palmaz-Schatz 245 (61%)
Wiktor 131 (32%)
Gianturco-Roubin 15 (4%)
Angiostent 6 (1%)
Bard XT 5 (1%)
ACS Multilink 1
NIR Stent 1
Wallstent 1
No. of stents/lesion 1.2 6 0.4
Inflation pressure (atm) 15 6 3
*Modified by Ellis et al. (27). Data presented are number (%) of lesions or
mean value 6 SD. ACC/AHA 5 American College of Cardiology/American
Heart Association; LAD 5 left anterior descending coronary artery; LCx 5 left
circumflex artery; PTCA 5 percutaneous transluminal coronary angioplasty;
RCA 5 right coronary artery; TIMI 5 Thrombolysis in Myocardial Infarction.
Table 3. Major Cardiac Events During 6-Month Follow-Up in 463
Patients With Successful Coronary Stenting
Event ,30 Days .30 Days Total
Death 1 (0.2%) 6 (1.3%) 7 (1.5%)
MI 2 (0.4%) 2 (0.4%) 4 (0.8%)
Bypass surgery 0 2 (0.4%) 2 (0.4%)
Repeat PTCA
Target site 2 (0.4%) 67 (14.5%) 69 (14.9%)
Other site 0 30 (6.5%) 30 (6.5%)
Any event 5 (1.1%) 104 (22.5%) 109 (23.5%)
Data presented are number (%) of patients. MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty.
Table 4. Acute Results and 6-Month Follow-Up (405 lesions)
Reference diameter (mm)
Before 3.04 6 0.50
After 3.03 6 0.50
Follow-up 3.03 6 0.49
Minimal lumen
diameter (mm)
Before 0.78 6 0.45
After 2.57 6 0.43
Follow-up 1.78 6 0.70
Percent diameter stenosis
Before 73 6 15
After 10 6 10
Follow-up 37 6 22
Acute gain (mm) 1.80 6 0.56
Late loss (mm) 0.79 6 0.64
Net gain (mm) 1.01 6 0.76
Restenosis rate* 105 (26%)
Total occlusion
at follow-up
6 (1.5%)
*Diameter stenosis .50% at follow-up. Data presented are mean value 6
SD or number (%) of lesions.
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tive restenosis, defined as .50% diameter stenosis at follow-
up.
None of the clinical variables studied were associated with
increased late lumen loss or increased restenosis rate (Table
5). In particular, diabetes, unstable angina and CS of an
infarct-related lesion were not associated with higher resteno-
sis rates. The outcome at follow-up angiography was also
similar for CS performed for a restenotic lesion or for a de
novo lesion.
Except for stenosis length, none of the lesion-related vari-
ables listed in Table 6 were associated with an increased late
lumen loss in MLD or an increased risk of restenosis. Factors
such as stenosis location, TIMI flow grade before intervention
or the angiographic characteristics of the lesion did not affect
the risk of restenosis. Although there was a trend toward a
higher late loss in MLD and a higher risk of restenosis in
patients with more severe stenoses before CS, these differences
did not reach statistical significance.
As shown in Table 7, the implantation of multiple stents in
the same vessel, a high early gain and a low residual stenosis
after CS were significantly associated with an increased late
loss in MLD. The sole procedural factor significantly associ-
ated with a higher rate of qualitative restenosis was the
implantation of multiple stents.
The results of multivariate analysis are shown in Tables 8
and 9. Implantation of multiple stents and a high early gain
were independently associated with a higher late late loss in
MLD. The use of high inflation pressure and Palmaz-Schatz
stents was independently associated with a lower late loss in
MLD. When restenosis was defined as a qualitative variable,
implantation of multiple stents, stenosis length, small refer-
Table 5. Univariate Predictors of Restenosis: Clinical Variables
Late Loss
(mm)*
Restenosis
Rate†
Age (yr)
,53 (n 5 129) 0.79 6 0.61 26%
53–64 (n 5 139) 0.84 6 0.65 27%
.64 (n 5 137) 0.75 6 0.65 25%
Men (n 5 350) 0.78 6 0.64 26%
Women (n 5 55) 0.86 6 0.60 27%
Diabetes mellitus
Yes (n 5 81) 0.82 6 0.74 26%
No (n 5 324) 0.79 6 0.61 26%
Smoker
Yes (n 5 286) 0.80 6 0.64 28%
No (n 5 119) 0.77 6 0.63 22%
Hypertension
Yes (n 5 155) 0.81 6 0.67 30%
No (n 5 250) 0.79 6 0.62 24%
Hypercholesterolemia
Yes (n 5 244) 0.75 6 0.64 25%
No (n 5 161) 0.86 6 0.64 27%
Family history of CAD
Yes (n 5 198) 0.81 6 0.66 27%
No (n 5 207) 0.78 6 0.62 25%
Unstable angina
Yes (n 5 145) 0.78 6 0.66 27%
No (n 5 260) 0.80 6 0.63 25%
Infarct-related lesion
Yes (n 5 112) 0.86 6 0.62 27%
No (n 5 293) 0.77 6 0.64 26%
Previous PTCA at same site
Yes (n 5 80) 0.82 6 0.60 31%
No (n 5 325) 0.79 6 0.64 25%
*Mean value 6 SD. †Diameter stenosis .50% at follow-up. Abbreviations as
in Tables 1 and 3.
Table 6. Univariate Predictors of Restenosis: Lesion-Related
Variables
Late Loss
(mm)*
Restenosis
Rate†
Dilated site
LAD (n 5 203) 0.76 6 0.55 25%
LCx (n 5 49) 0.90 6 0.73 39%
RCA (n 5 128) 0.81 6 0.66 24%
Saphenous vein graft (n
5 25)
0.78 6 0.93 20%
ACC/AHA classification‡
A (n 5 38) 0.80 6 0.58 18%
B1 (n 5 105) 0.78 6 0.62 25%
B2 (n 5 204) 0.76 6 0.63 25%
C (n 5 58) 0.93 6 0.71 34%
TIMI flow grade
0–1 (n 5 54) 0.81 6 0.69 24%
2 (n 5 28) 0.74 6 0.79 32%
3 (n 5 323) 0.80 6 0.62 26%
Calcification
Yes (n 5 125) 0.72 6 0.59 24%
No (n 5 280) 0.83 6 0.65 27%
Eccentric stenosis
Yes (n 5 183) 0.77 6 0.81 25%
No (n 5 222) 0.81 6 0.62 27%
Lesion length (mm)
,6 (n 5 139) 0.61 6 0.58§ 14%§
6–10 (n 5 166) 0.86 6 0.66§ 30%§
.10 (n 5 100) 0.93 6 0.68§ 37%§
Bifurcation lesion
Yes (n 5 87) 0.80 6 0.57 33%
No (n 5 318) 0.79 6 0.66 24%
Bend location
Yes (n 5 65) 0.88 6 0.72 34%
No (n 5 340) 0.78 6 0.62 24%
Thrombus
Yes (n 5 73) 0.84 6 0.64 26%
No (n 5 332) 0.78 6 0.62 26%
Reference diameter (mm)
,2.8 (n 5 137) 0.73 6 0.60 28%
2.8–3.2 (n 5 127) 0.79 6 0.61 24%
.3.2 (n 5 139) 0.85 6 0.69 25%
Diameter stenosis
before procedure
,65% (n 5 122) 0.69 6 0.50 20%
65–75% (n 5 136) 0.80 6 0.67 27%
.75% (n 5 147) 0.88 6 0.69 30%
*Mean value 6 SD. †Diameter stenosis .50% at follow-up. ‡Modified by
Ellis et al. (27). §p , 0.0001. Abbreviations as in Table 2.
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ence diameter and stent type other than Palmaz-Schatz were
independent predictors of restenosis (Table 9).
Discussion
The use of CS has increased dramatically in the past few
years. Recent studies, performed in highly selected patient
groups, have shown that the risk of restenosis is reduced but
not abolished after CS (7,8). Identification of risk factors for
in-stent restenosis, as well as comparison with the risk factors
for restenosis after BA, may provide a better understanding of
the potential of CS to treat patients with CAD. Indeed, as the
mechanisms of restenosis after CS differ from those after BA
(9,10), factors that have been associated with high restenosis
rates after BA will not necessarily affect restenosis after CS.
Previous studies have already described risk factors for
in-stent restenosis (Carrozza et al. [4] used the Palmaz-Schatz
stent in 250 patients; Ellis et al. [5] used the Palmaz-Schatz
stent in 206 patients; Strauss et al. [25] used the Wallstent in
214 patients; Eeckhout et al. [26] used the Wallstent and
Palmaz-Schatz and Wiktor stents in 243 patients; de Jaegere et
al. [30] used the Wiktor stent in 91 patients). However, at the
time these studies were performed, oral anticoagulant agents
were given for at least 2 months after the procedure, the rate
of subacute thrombosis was high and the importance of high
pressure inflations for adequate stent deployment was not
widely appreciated. Recent improvements in the technique of
stent implantation and the introduction of new antiplatelet
regimens, including ticlopidine, have made CS an extremely
safe procedure. Because of these advances and the results of
randomized studies comparing CS and BA, CS is now performed
in a high proportion of patients undergoing PTCA. The present
study, reporting the angiographic follow-up of 463 consecutive
patients who had high pressure inflation of balloon-expandable
coronary stents and who were treated with a combination of
ticlopidine and aspirin, is thus likely to reflect the angiographic
outcome in patients undergoing CS in current clinical practise.
Diabetes and other CAD risk factors. Multiple studies
have tried to relate coronary risk factors to the occurrence of
restenosis after BA. In most of these studies, variables such as
hypertension, smoking habits or a family history of CAD were
not associated with an increased risk of restenosis. In contrast,
diabetes has consistently been reported to be a risk factor for
restenosis after BA (19–21). In the present study, none of the
clinical variables studied were associated with an increased risk
of restenosis after CS.
We observed a similar extent of late loss in MLD and a
similar binary restenosis rate in diabetic and nondiabetic
patients. These results are concordant with those of most
previous reports in which diabetes was not found to be a risk
factor for in-stent restenosis (5,31), but differ from those
reported by Carrozza et al. (15), who suggested that the
restenosis rate was indeed increased in diabetic patients un-
dergoing CS. Differences in study groups may account for this
discrepancy; in the study of Carrozza et al., a majority of the
diabetic patients underwent CS for saphenous vein graft
lesions; in the present study, a majority (94%) of the proce-
dures were performed in native vessels. The reasons for the
increased restenosis rate after BA in diabetic patients are
unknown. It has been suggested that the degree of neointimal
hyperplasia might be greater as a consequence of a stimulatory
effect of growth factors such as insulin-like growth factor-1 on
Table 8. Multiple Linear Regression for the Dependent Variable of
Late Loss
Independent
Variable Coeff SE
p
Value
No. of stents 0.34 0.07 0.0001
Acute gain (mm) 0.21 0.06 0.0002
Palmaz-Schatz stent 20.18 0.06 0.005
Inflation pressure (atm) 20.02 0.01 0.02
Coeff 5 coefficient.
Table 9. Multiple Logistic Regression Analysis for the Dependent
Variable of Restenosis*
Independent
Variable Coeff SE
p
Value OR (95% CI)
No. of stents 0.83 0.26 0.001 2.29 (1.37–3.82)
Palmaz-Schatz stent 20.68 0.25 0.007 0.50 (0.31–0.83)
Stenosis length (mm) 0.05 0.02 0.008 1.06 (1.01–1.10)
Ref diam (mm) 20.58 0.26 0.02 0.56 (0.34–0.93)
*Diameter stenosis .50% at follow-up. CI 5 confidence interval; OR 5
odds ratio; Ref diam 5 reference diameter.
Table 7. Univariate Predictors of Restenosis: Procedural Variables
Late Loss
(mm)*
Restenosis
Rate†
Stent indication
Bail-out (n 5 55) 0.77 6 0.62 29%
Suboptimal result (n 5 264) 0.81 6 0.64 26%
Elective (n 5 86) 0.76 6 0.66 23%
Type of stent
Palmaz-Schatz (n 5 245) 0.73 6 0.61 22%
Wiktor (n 5 131) 0.85 6 0.64 31%
No. of stents
1 (n 5 343) 0.74 6 0.62‡ 22%‡
2 (n 5 51) 1.02 6 0.62‡ 39%‡
3 (n 5 11) 1.46 6 0.66‡ 72%‡
Inflation pressure (atm)
,14 (n 5 88) 0.92 6 0.73 31%
14–16 (n 5 202) 0.77 6 0.62 25%
.16 (n 5 98) 0.70 6 0.58 22%
Acute gain (mm)
,1.5 (n 5 138) 0.62 6 0.52§ 26%
1.5–2 (n 5 136) 0.86 6 0.63§ 29%
.2 (n 5 130) 0.91 6 0.71§ 22%
% DS after stenting
,5% (n 5 143) 0.83 6 0.64\ 20%
5–15% (n 5 147) 0.88 6 0.68\ 30%
.15% (n 5 115) 0.64 6 0.55\ 29%
*Mean value 6 SD. †Diameter stenosis (DS) .50% at follow-up. ‡p ,
0.0001. §p , 0.001. \p , 0.01.
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vascular smooth muscle cells (32). Alternatively, it has recently
been shown that the specific feature of atherectomy specimens
from restenotic lesions retrieved in diabetic patients was not
enhanced smooth muscle proliferation but rather a greater
fibrotic response that may favor vessel constriction (33). Our
results showing that diabetes is not a risk factor for restenosis
after CS, a situation in which vessel remodeling is abolished
and in which restenosis is mainly the consequence of neointi-
mal hyperplasia, do not support the hypothesis that diabetic
patients have an increased proliferative response after arterial
injury.
Unstable angina, infarct-related lesions, thrombus-containing
lesions and total occlusions. High rates of restenosis have
been reported when BA is performed in an unstable setting
(e.g., unstable angina, infarct-related vessels) (22,23,34). Sim-
ilar results have been reported when BA is performed in
vessels that are totally occluded before the procedure (24) or in
lesions that contain thrombus (35,36). The common feature of
these subgroups of patients is the unstable nature of the dilated
site or the presence of superimposed residual thrombus after
angioplasty, or both (35). The higher rate of restenosis in this
setting is, at least in part, related to a higher risk (10% to 20%)
of total occlusion at the dilated site during the follow-up period
(22,23,35,36).
The present study shows that these patients are not at a
higher risk of restenosis after CS. This result is, at least in part,
a consequence of the very low rate of total occlusion at the
dilated site during the follow-up period. Late total occlusion of
the stented segment occurred in only six patients (1.5%). The
exact mechanism(s) responsible for the effect of stents on late
occlusion are not known but may be related to a consolidation
of ruptured atherosclerotic plaques, to an improved early
result with better postprocedural flow (which would decrease
the risk of thrombosis) or to an antithrombotic effect of
ticlopidine. Recent studies have shown that the combination of
aspirin and ticlopidine—a potent antiplatelet agent (37)—is
very effective in preventing subacute stent thrombosis (12); its
effect on late occlusion is unknown.
Restenotic lesions. Repeat BA for early restenosis has
been associated with high restenosis rates (38,39). Restenotic
lesions have a different substrate from that of primary lesions
and may predispose to a higher incidence of a second resten-
osis. Similarly, previous studies have reported a higher resten-
osis rate after stenting of restenotic versus de novo lesions
(5,31). In contrast, in the present study, lumen narrowing after
CS was the same whether or not a previous BA had been
performed at the target site. Further randomized studies are
needed to demonstrate whether CS is superior to BA for
restenotic lesions.
Lesion location and angiographic characteristics. As in
previous studies (5,31), the location of the stented lesion had
no impact on restenosis after CS. Previous studies have
suggested that LAD location was a risk factor for restenosis
after BA (40). A recent report by Wong et al. (41), suggesting
that the antirestenosis effect of stenting versus BA might be
greater in LAD vessels, is consistent with these observations.
In the present study, the sole qualitative angiographic
variable associated with restenosis after CS was stenosis length.
Lesion length has also been cited as a risk factor for restenosis
after BA (42).
A small reference diameter was associated with a higher
risk of binary restenosis on multivariate analysis; in contrast, it
was not associated with a higher late lumen loss. This may be
explained by the fact that a given degree of neointimal
thickening is more likely to induce .50% diameter stenosis in
a small vessel versus a large vessel. A previous meta-analysis of
the Belgian Netherlands Stent (BENESTENT) study and Stent
Restenosis Study (STRESS) has reported that CS was not
significantly better than BA in ,2.6-mm vessels (14). Our
results again suggest that a small reference diameter is a
limitation of CS in terms of restenosis.
Procedural factors. In this study, most of the predictors of
restenosis were procedural variables. Previous reports have
shown a relation between multiple stents and restenosis
(5,25,26). We observed an increasing late lumen loss and
restenosis rate with the number of stents implanted. The
mechanism by which multiple stents are associated with resten-
osis is unknown; one explanation may be related to overlap-
ping of the stents, which may provoke a greater degree of
neointimal proliferation; alternatively, the increased length of
the stented segment may also evoke a greater degree of
proliferation. Further studies will have to determine whether
the use of longer stents results in an improvement in the
method of overlapping stents in the case of long lesions.
A high early gain and its correlate, low residual stenosis
after CS, were associated with a higher late loss in MLD. This
relation between early gain and late lumen loss has been
described for BA and also for CS (43). In contrast, we observed
a trend toward a lower rate of restenosis in the case of low
residual stenosis. This underscores the fact that, despite the
risk of a higher late lumen loss, it is necessary to obtain a high
early gain and low residual stenosis to reduce the incidence of
restenosis.
The indication for stenting was not found to be a risk factor
for restenosis in the present study. The restenosis rate after
elective CS was not significantly different from that after
bail-out CS or after CS done because of a suboptimal result
after BA. Similar results have been reported by Strauss et al.
(25) after implantation of the coronary Wallstent. Other
procedural variables, such as the type of stent or inflation
pressure, had no significant impact on the risk of restenosis by
univariate analysis, but were associated with restenosis by
multivariate analysis. Previous studies have already suggested
that the restenosis rate may be higher with Wiktor stents than
with Palmaz-Schatz stents (44), and that the technique of stent
implantation may affect the risk of subsequent restenosis (45).
Conclusions. This study demonstrates an acceptable rate
(26%) of angiographic restenosis after CS in a series of
consecutive patients. Although some procedural risk factors
were identified, the risk of restenosis was not related to most of
the procedural variables tested. Of particular interest is the
lack of effect of variables that have been previously associated
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with an increased risk of restenosis after BA, such as diabetes,
total occlusion before the procedure, infarct-related vessel and
unstable angina. These results suggest a major benefit of CS in
these subgroups of patients. This will have to be confirmed by
randomized studies.
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